Aripiprazole in l-dopa-induced dyskinesias: A one-year open-label pilot study

Giuseppe Meco; Paola Stirpe; Fabrizio Edito; Carlo Purcaro; Marcella Valente; Silvia Bernardi; Nicola Vanacore

doi:10.1007/s00702-009-0231-z

Aripiprazole in l-dopa-induced dyskinesias: A one-year open-label pilot study

Giuseppe Meco, Paola Stirpe, Fabrizio Edito, Carlo Purcaro, Marcella Valente, Silvia Bernardi, Nicola Vanacore

Istituto San Raffaele Pisana

Research output: Contribution to journal › Article

Abstract

Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor. The aim of the present study was to evaluate, in an open-label pilot study, the effects and safety of very small doses of aripiprazole on l-dopa-induced dyskinesia of a group of PD patients who did not show a significant clinical benefit by pharmacological treatment with amantadine and mirtazapine. Twelve PD patients with peak-dose LID were enrolled in a period of 1 year. Aripiprazole dosage was of 0.625 mg/day. The ten patients who continued taking aripiprazole displayed a significant decrease in the intensity and frequency of dyskinesias in all parts of the body, particularly in trunk movements (AIMS score T ₀ = 14.1 ± 3.6 vs. final score 2.4. ± 2.6; P = 0.005). Our study suggests that aripiprazole at very low doses is tolerated and could be efficacy in treating LID.

Original language	English
Pages (from-to)	881-884
Number of pages	4
Journal	Journal of Neural Transmission
Volume	116
Issue number	7
DOIs	https://doi.org/10.1007/s00702-009-0231-z
Publication status	Published - Jul 2009

Keywords

Aripiprazole
L-Dopa-induced dyskinesias
Parkinson's disease

ASJC Scopus subject areas

Biological Psychiatry
Neurology
Clinical Neurology
Psychiatry and Mental health

Access to Document

10.1007/s00702-009-0231-z

Fingerprint Dive into the research topics of 'Aripiprazole in l-dopa-induced dyskinesias: A one-year open-label pilot study'. Together they form a unique fingerprint.

Cite this

Meco, G., Stirpe, P., Edito, F., Purcaro, C., Valente, M., Bernardi, S., & Vanacore, N. (2009). Aripiprazole in l-dopa-induced dyskinesias: A one-year open-label pilot study. Journal of Neural Transmission, 116(7), 881-884. https://doi.org/10.1007/s00702-009-0231-z

@article{03e60f3f49b74893b84ba021a8141d9c,

title = "Aripiprazole in l-dopa-induced dyskinesias: A one-year open-label pilot study",

abstract = "Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor. The aim of the present study was to evaluate, in an open-label pilot study, the effects and safety of very small doses of aripiprazole on l-dopa-induced dyskinesia of a group of PD patients who did not show a significant clinical benefit by pharmacological treatment with amantadine and mirtazapine. Twelve PD patients with peak-dose LID were enrolled in a period of 1 year. Aripiprazole dosage was of 0.625 mg/day. The ten patients who continued taking aripiprazole displayed a significant decrease in the intensity and frequency of dyskinesias in all parts of the body, particularly in trunk movements (AIMS score T 0 = 14.1 ± 3.6 vs. final score 2.4. ± 2.6; P = 0.005). Our study suggests that aripiprazole at very low doses is tolerated and could be efficacy in treating LID.",

keywords = "Aripiprazole, L-Dopa-induced dyskinesias, Parkinson's disease",

author = "Giuseppe Meco and Paola Stirpe and Fabrizio Edito and Carlo Purcaro and Marcella Valente and Silvia Bernardi and Nicola Vanacore",

year = "2009",

month = jul,

doi = "10.1007/s00702-009-0231-z",

language = "English",

volume = "116",

pages = "881--884",

journal = "Journal of Neural Transmission",

issn = "0300-9564",

publisher = "Springer-Verlag Wien",

number = "7",

}

TY - JOUR

T1 - Aripiprazole in l-dopa-induced dyskinesias

T2 - A one-year open-label pilot study

AU - Meco, Giuseppe

AU - Stirpe, Paola

AU - Edito, Fabrizio

AU - Purcaro, Carlo

AU - Valente, Marcella

AU - Bernardi, Silvia

AU - Vanacore, Nicola

PY - 2009/7

Y1 - 2009/7

N2 - Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor. The aim of the present study was to evaluate, in an open-label pilot study, the effects and safety of very small doses of aripiprazole on l-dopa-induced dyskinesia of a group of PD patients who did not show a significant clinical benefit by pharmacological treatment with amantadine and mirtazapine. Twelve PD patients with peak-dose LID were enrolled in a period of 1 year. Aripiprazole dosage was of 0.625 mg/day. The ten patients who continued taking aripiprazole displayed a significant decrease in the intensity and frequency of dyskinesias in all parts of the body, particularly in trunk movements (AIMS score T 0 = 14.1 ± 3.6 vs. final score 2.4. ± 2.6; P = 0.005). Our study suggests that aripiprazole at very low doses is tolerated and could be efficacy in treating LID.

AB - Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor. The aim of the present study was to evaluate, in an open-label pilot study, the effects and safety of very small doses of aripiprazole on l-dopa-induced dyskinesia of a group of PD patients who did not show a significant clinical benefit by pharmacological treatment with amantadine and mirtazapine. Twelve PD patients with peak-dose LID were enrolled in a period of 1 year. Aripiprazole dosage was of 0.625 mg/day. The ten patients who continued taking aripiprazole displayed a significant decrease in the intensity and frequency of dyskinesias in all parts of the body, particularly in trunk movements (AIMS score T 0 = 14.1 ± 3.6 vs. final score 2.4. ± 2.6; P = 0.005). Our study suggests that aripiprazole at very low doses is tolerated and could be efficacy in treating LID.

KW - Aripiprazole

KW - L-Dopa-induced dyskinesias

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=67651149481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651149481&partnerID=8YFLogxK

U2 - 10.1007/s00702-009-0231-z

DO - 10.1007/s00702-009-0231-z

M3 - Article

C2 - 19533295

AN - SCOPUS:67651149481

VL - 116

SP - 881

EP - 884

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 7

ER -